[Newsmp] Major global big pharmaceutical companies expanded their sales significantly in the first quarter while the Omicron variant prevailed worldwide.In particular, the growth of companies with COVID-19 treatments or vaccines such as Pfizer, Moderna, AstraZeneca, and MSD was remarkable.The compan

[Newsmp] In the first quarter, it was found that sales of over-the-counter (OTC) drugs from top pharmaceutical companies increased significantly amid the continued shortage of OTC medicines such as cold medicines in the aftermath of the Omicron variant of COVID-19.According to Newsmp’s analysis of t

[Newsmp] In the first quarter, when the Omicron variant of COVID-19 was severe, all major pharmaceutical companies achieved good results.Newsmp compiled the disclosures of the five major pharmaceutical companies, and it was found that the average sales growth rate of them in the first quarter was 19

[Newsmp] In April, the bio-health exports sector reached a record monthly high.According to the Ministry of Trade, Industry and Energy (MOTIE), exports in the bio-health industry in April recorded $1.26 billion, up 14.2% from the same period last year, continuing double-digit growth for four consecu

[Newsmp] In the first quarter, Korea’s pharmaceutical trade deficit exceeded $900 million, with a deficit exceeding $300 million from the U.S. and Germany. On the contrary, Korea had a surplus of $300 million from Australia and $100 million from Taiwan.According to the Korea Customs Service, Korea’s

[Newsmp] Pfizer Pharmaceutical Korea’s retained earnings have soared by more than KRW 90 billion over the past year to KRW 300 billion.Newsmp tallied the income statements of multinational companies’ subsidiaries in Korea, whose closing accounts are between September and December, and found that of

[Newsmp] Multinational pharmaceutical companies’ subsidiaries in Korea are tightly cracking down on the amount of donations in the COVID-19 situation.Following 2020, the first year of COVID-19, the third and fourth pandemics continued throughout the last year, and they further reduced donations.News

[Newsmp] The cost of goods sold ratio (COGS) of multinational pharmaceutical companies’ subsidiaries in Korea was close to the 80% mark on average.Pfizer Pharmaceutical Korea, which has greatly is sales with the influence of the COVID-19 vaccine, has raised the average COGS ratio of multination phar

[Newsmp] Last year, Pfizer Pharmaceutical Korea recorded sales growth of more than 300% with the COVID-19 vaccine, and the average sales growth rate of multinational pharmaceutical companies was close to the 30% mark.Newsmp tallied the income statements of multinational companies’ subsidiaries in Ko

[Newsmp] In March this year, institutional investors who had largely liquidated their stake in Celltrion started courting again.Individual investors regained their loyalty to Shinpoong Pharmaceutical and Celltrion and bought Ildong Pharmaceutical.According to the Korean Exchange, institutional inves

[Newsmp] Six of the pharmaceutical companies ranked in the top 100 in annual sales among 1,328 KOSDAQ-listed components whose closing accounts are in December.According to the Korea Exchange’s KOSDAQ market fiscal year report, Seegene was the only pharmaceutical and bio company to achieve more than

[Newsmp] Exports in the biohealth sector including pharmaceuticals, which had gradually declined since their peak in December, have surged.According to the Ministry of Commerce Industry and Energy, Korea’s total exports in March reached $63.48 billion, an increase of 18.2% year-on-year and a record

[Newsmp] In 2020, the first year of COVID-19, the total R&D costs in the pharmaceutical manufacturing industry exceeded KRW 2 trillion.This is an increase of nearly KRW 400 billion from the previous year in 2019, and its proportion in the manufacturing sector has surpassed 3%.At the same time, R&D e

[Newsmp] Korean listed pharmaceutical companies’ entertainment costs, which had decreased due to COVID-19, has increased again.Newsmp compiled data from 44 listed pharmaceutical companies whose closing account is in November and December and found that the combined entertainment expenses amounted to

[Newsmp] As exports of pharmaceutical products have decreased significantly since its peak in December last year, there are significant differences depending on the code.The Korea Customs Service’s HS-30 based pharmaceutical products exports in February fell by half from last December, but the Korea

Exports of diagnostic reagents continue to boom in the aftermath of the spread of the omicron variant, but the trade deficit for pharmaceutical products has widened due to the impact of vaccine imports.According to the data from the Korea Customs Service, monthly exports of diagnostic reagents (HS38

The Korean Ministry of Food and Drug Safety (MFDS) approved a total of 36 patents in February.According to the MFDS’ information platform (https://nedrug.mfds.go.kr/), Tabrecta-related (Novartis) patents accounted for the most with six, followed by Invega Sustenna Inj. (Janssen Korea) with five amon

Retail sales of pharmaceuticals expanded in January, but the record-breaking streak stopped.According to data compiled by Statistics Korea, monthly retail sales stood at KRW 2.86 trillion in January, maintaining the KRW 2 trillion mark for the ninth consecutive month since it surpassed KRW 2 trillio

Pharmaceutical stocks have regained vigor after a long time, occupying a higher place in share price growth.According to the Korea Exchange, 11 pharmaceutical stocks were listed in the top 100, including three stocks in the top 10 in the KOSPI market in February.In particular, Ildong Pharmaceutical

Analysts say Russia’s invasion of Ukraine will damage Korea’s medical device industry.It is expected that the impact in the medical instruments sector will be greater than that of pharmaceutical products in the healthcare industry.On the 28th, Korea Bio-Economy Research Center (KBERC) from KoreaBIO